Tim Clackson
- Hematology top 0.5%
- Chronic Myeloid Leukemia Treatments 30
- Molecular Biology top 0.5%
- RNA Interference and Gene Delivery 15
- PI3K/AKT/mTOR signaling in cancer 10
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 26
- Virus-based gene therapy research 25
- Oncology top 1%
- CAR-T cell therapy research 12
-
- Lung Cancer Treatments and Mutations 13
-
- Acute Lymphoblastic Leukemia research 11
- Co-authors
- James A. WellsVictor M. RiveraGreg WinterAndrew D. GriffithsHennie R. HoogenboomRoy M. PollockMichael GilmanDennis A. Holt
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Tim Clackson
101 papers receiving 9.2k citations
Hit Papers
Peers
Comparison fields: 5 of 151
- Hematology 1.3k
- Molecular Biology 6.3k
- Radiology, Nuclear Medicine and Imaging 2.0k
- Genetics 895
- Oncology 1.7k
Countries citing papers authored by Tim Clackson
This map shows the geographic impact of Tim Clackson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Clackson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Clackson more than expected).
Fields of papers citing papers by Tim Clackson
This network shows the impact of papers produced by Tim Clackson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Clackson. The network helps show where Tim Clackson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Tim Clackson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 8 | |
| 2 | 2014 | 123 | |
| 3 | 2012 | 273 | |
| 4 | Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemiasbreakdown → | 2012 | 527 |
| 5 | 2011 | 40 | |
| 6 | 2011 | 87 | |
| 7 | 2011 | 4 | |
| 8 | 2010 | 1 | |
| 9 | 2009 | 18 | |
| 10 | 2009 | 23 | |
| 11 | Anti-proliferative activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in combination with cytotoxic and targeted agents in sarcoma and endometrial cancer models | 2008 | 1 |
| 12 | Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents | 2004 | 18 |
| 13 | Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy. | 2004 | 19 |
| 14 | Phage display : a practical approach | 2004 | 82 |
| 15 | 2002 | 74 | |
| 16 | 2002 | 82 | |
| 17 | 2002 | 39 | |
| 18 | 2000 | 93 | |
| 19 | 1998 | 25 | |
| 20 | 1989 | 289 |
About Tim Clackson
Tim Clackson is a scholar working on Hematology, Genetics and Oncology, having authored 103 papers that have together received 9.5k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (30 papers), Chronic Lymphocytic Leukemia Research (26 papers), Virus-based gene therapy research (25 papers), RNA Interference and Gene Delivery (15 papers), Lung Cancer Treatments and Mutations (13 papers), CAR-T cell therapy research (12 papers), Acute Lymphoblastic Leukemia research (11 papers) and PI3K/AKT/mTOR signaling in cancer (10 papers). The work is most often cited by research in Hematology (1.3k citations), Molecular Biology (6.3k citations) and Radiology, Nuclear Medicine and Imaging (2.0k citations). Tim Clackson has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include James A. Wells, Victor M. Rivera, Greg Winter, Andrew D. Griffiths, Hennie R. Hoogenboom, Roy M. Pollock, Michael Gilman, Dennis A. Holt, Narayana I. Narasimhan and Terence P. Keenan. Their work appears in journals such as Blood, Cancer Research, Journal of Clinical Oncology, Molecular Therapy and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.